A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults
NCT04758962
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Virus Diseases
Interventions
BIOLOGICAL:
1 µg CoV2 SAM (LNP)
Sponsor
GlaxoSmithKline